US stocks slide amid dispute over Fed funds and spiking COVID-19 cases – Business Insider

This post was originally published on this site

  • US stocks fell on Friday as conflict over the use of Federal Reserve funds offset positive developments for vaccine distribution.
  • Treasury Secretary Steven Mnuchin urged the Fed on Thursday to return funds set aside for emergency lending, setting up several relief programs for year-end expiration.
  • The move marked a rare bout of disagreement, as the Fed replied with a call to extend “the full suite of emergency facilities” past their upcoming deadlines.
  • Pfizer and BioNTech both gained after applying for emergency-use authorization for their experimental coronavirus vaccine. The FDA’s vetting process is set to take a few weeks, teeing the shot up for an early 2021 rollout.
  • Watch major indexes update live here.

US equities dipped on Friday as disagreement over the use of federal relief funds offset encouraging progress toward COVID-19 vaccine approval.

Indexes’ declines began late Thursday after Treasury Secretary Steven Mnuchin called on the Federal Reserve to return funds set aside for several emergency lending programs. The decision sets a December 31 expiration date for five facilities, including the Municipal Liquidity Facility and both corporate-credit programs.

Mnuchin said that, while some corners of the economy continue to struggle through the pandemic, additional fiscal stimulus would help them more than taking on more debt.

The Fed quickly responded with a rare public statement, saying the Treasury should extend “the full suite of emergency facilities.” The programs continue to serve “as a backstop for our still-strained and vulnerable economy,” the central bank added.

Here’s where US indexes stood at the 4 p.m. ET market close on Friday:

Read more: Warren Buffett compared the pandemic to a ‘hurricane,’ praised the government’s rapid response in the spring, and called for more small-business aid at a virtual event this week

“It would be odd for the Fed to make this statement if it believed Mnuchin was legally obliged to act as he did,” Michael Feroli, chief US economist at JPMorgan, said in a note. “Rather, it seems like the Fed is making clear where they stand on this issue.”

The unusual conflict between economic policymakers loomed over positive news on the vaccine front. Pfizer and BioNTech applied for emergency-use authorization from the US Food and Drug Administration on Friday for their experimental coronavirus vaccine. Both companies gained on the news.

The FDA’s vetting process is set to take a few weeks, and vulnerable populations could receive the shot in early 2021.

Approval for a vaccine comes at a critical point for the US economy. The country reported a record 182,832 new COVID-19 cases on Thursday, according to The COVID Tracking Project. Daily deaths came in just below 2,000, and the number of Americans hospitalized with the virus passed 80,000.

Read more: 600 units and almost 20 flips: Here’s how Ashley Wilson created a real-estate investment empire leveraging just 2 simple strategies

Major cities continue to implement stricter lockdown measures to combat the virus’s community spread. The restrictions threaten to cut into critical holiday season spending and slow the US economic recovery even further. California Governor Gavin Newsom set a month-long curfew on Thursday, and public health authorities are warning against traveling for Thanksgiving.

Indicators including retail sales growth and jobless claims surprised to the downside in recent weeks, suggesting the rebound is already losing momentum.

The dispute marks an unusual bout of discord between the country’s top two economic policymakers. While the Fed and the Treasury worked hand-in-hand at the start of the pandemic to introduce the facilities, their disagreement jeopardizes a coordinated policy response moving forward.

Read more: Markets are headed down one of 3 paths in 2021, UBS says. Here’s how investors can maximize their profits in all of them.

Gilead shares fell after World Health Organization officials advised against treating COVID-19 patients with its remdesivir drug. There is “no evidence” the drug improves chances of survival or the need for ventilation, the organization said in a medical journal.

Bitcoin surged as high as $18,821.70 before paring some gains. The jump pushed the cryptocurrency even closer to retaking its 2017 high.

Spot gold increased 0.7%, to $1,879.81 per ounce, at intraday highs. The US dollar declined against the majority of its Group-of-10 peers, while Treasury yields slid.

Oil prices rose. West Texas Intermediate crude gained as much as 1.4%, to $42.32 per barrel. Brent crude, oil’s international benchmark, climbed 2.3%, to $45.21 per barrel, at intraday highs.

Now read more markets coverage from Markets Insider and Business Insider:

‘I still think there’s a long way to go’: A crypto CEO breaks down why he’s bullish on Bitcoin even after its surge back to $18,000 – and shares the other cryptocurrency he thinks is here to stay

Congress must pass new stimulus now to fend off another virus-driven economic slowdown, says one Fed president

Gen Z’s surging economic power will permanently change the investing landscape over the next decade, Bank of America says

This post was originally published on *this site*